We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
05 Apr 21
BNT162b2 was 100% effective against severe Covid-19, as defined by the CDC, and 95.3% effective against severe Covid-19,…
26 Mar 21
The Phase 1/2/3 trial will evaluate two-dose mRNA vaccine BNT162b2, administered 21 days apart, in three age groups
25 Mar 21
The analysis confirmed that the AZD1222 vaccine is 76% effective against symptomatic Covid-19, and 100% against severe disease…
23 Mar 21
AZD1222 showed 79% vaccine efficacy in preventing symptomatic Covid-19 and 100% efficacy against severe Covid-19 and hospitalisation
12 Mar 21
The MoH analysis showed at least 97% vaccine effectiveness against symptomatic Covid-19 cases, and 94% against asymptomatic SARS-CoV-2…
26 Feb 21
The Phase 1/2/3 trial evaluates the safety and tolerability of a third dose of BNT162b2 and its effectiveness…
23 Feb 21
The Phase 2 trial is designed to determine the appropriate antigen dosage for Phase 3 evaluation of their…
19 Feb 21
The Phase 2/3 study will enrol healthy pregnant women, aged 18 years and older, and vaccinate them during…
04 Feb 21
The vaccine demonstrated 100% protection against severe disease, hospitalisation and death in the primary analysis of Phase 3…
01 Feb 21
The vaccine showed 72% effectiveness in the US and an overall 66% effectiveness in preventing Covid-19 after 28…